Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: A comparison with clozapine and placebo

Igor Elman, David S. Goldstein, Alan I. Green, Graeme Eisenhofer, Carol J. Folio, Courtney S. Holmes, David Pickar, Alan Breier

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Risperidone is an atypical antipsychotic drug that increases plasma norepinephrine (NE) levels, but the mechanism behind this effect is unclear. We measured arterial plasma levels of NE and other catechols during intravenous infusion of tritium-labeled NE (3H-NE) in risperidone-treated patients and compared their data with those from patients treated with clozapine or placebo. NE levels in risperidone patients were significantly higher than in placebo patients, but lower than in clozapine patients. Neither drug, however, had significant effect on plasma levels of the main neuronal metabolite of NE, dihydroxyphenylglycol (DHPG), suggesting that adrenoceptors blockade alone would not explain the NE findings. The rate of release of endogenous NE into the bloodstream (spillover) was elevated in both risperidone and clozapine patients in a manner that paralleled their NE levels; the NE clearance in both groups did not differ from placebo. Following 3H-NE infusion in risperidone-treated individuals, production of 3H-DHPG was normal, as it was in the clozapine group, suggesting that risperidone does not impede neuronal uptake or intraneuronal metabolism of NE by monoamine oxidase. Our data suggest that both risperidone and clozapine elevate plasma NE levels via enhanced neurotransmitter spillover, with risperidone producing a smaller effect.

Original languageEnglish
Pages (from-to)293-300
Number of pages8
JournalNeuropsychopharmacology
Volume27
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Risperidone
Clozapine
Schizophrenia
Norepinephrine
Placebos
Catechols
Tritium
Monoamine Oxidase
Intravenous Infusions
Adrenergic Receptors
Antipsychotic Agents
Neurotransmitter Agents

Keywords

  • Catecholamine
  • Clearance
  • DHPG
  • Schizophrenia
  • Spillover
  • Tritium-labeled norepinephrine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia : A comparison with clozapine and placebo. / Elman, Igor; Goldstein, David S.; Green, Alan I.; Eisenhofer, Graeme; Folio, Carol J.; Holmes, Courtney S.; Pickar, David; Breier, Alan.

In: Neuropsychopharmacology, Vol. 27, No. 2, 2002, p. 293-300.

Research output: Contribution to journalArticle

Elman, Igor ; Goldstein, David S. ; Green, Alan I. ; Eisenhofer, Graeme ; Folio, Carol J. ; Holmes, Courtney S. ; Pickar, David ; Breier, Alan. / Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia : A comparison with clozapine and placebo. In: Neuropsychopharmacology. 2002 ; Vol. 27, No. 2. pp. 293-300.
@article{ad4e9eb85bcf44b3b13b54e56e5b9883,
title = "Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: A comparison with clozapine and placebo",
abstract = "Risperidone is an atypical antipsychotic drug that increases plasma norepinephrine (NE) levels, but the mechanism behind this effect is unclear. We measured arterial plasma levels of NE and other catechols during intravenous infusion of tritium-labeled NE (3H-NE) in risperidone-treated patients and compared their data with those from patients treated with clozapine or placebo. NE levels in risperidone patients were significantly higher than in placebo patients, but lower than in clozapine patients. Neither drug, however, had significant effect on plasma levels of the main neuronal metabolite of NE, dihydroxyphenylglycol (DHPG), suggesting that adrenoceptors blockade alone would not explain the NE findings. The rate of release of endogenous NE into the bloodstream (spillover) was elevated in both risperidone and clozapine patients in a manner that paralleled their NE levels; the NE clearance in both groups did not differ from placebo. Following 3H-NE infusion in risperidone-treated individuals, production of 3H-DHPG was normal, as it was in the clozapine group, suggesting that risperidone does not impede neuronal uptake or intraneuronal metabolism of NE by monoamine oxidase. Our data suggest that both risperidone and clozapine elevate plasma NE levels via enhanced neurotransmitter spillover, with risperidone producing a smaller effect.",
keywords = "Catecholamine, Clearance, DHPG, Schizophrenia, Spillover, Tritium-labeled norepinephrine",
author = "Igor Elman and Goldstein, {David S.} and Green, {Alan I.} and Graeme Eisenhofer and Folio, {Carol J.} and Holmes, {Courtney S.} and David Pickar and Alan Breier",
year = "2002",
doi = "10.1016/S0893-133X(02)00314-7",
language = "English",
volume = "27",
pages = "293--300",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia

T2 - A comparison with clozapine and placebo

AU - Elman, Igor

AU - Goldstein, David S.

AU - Green, Alan I.

AU - Eisenhofer, Graeme

AU - Folio, Carol J.

AU - Holmes, Courtney S.

AU - Pickar, David

AU - Breier, Alan

PY - 2002

Y1 - 2002

N2 - Risperidone is an atypical antipsychotic drug that increases plasma norepinephrine (NE) levels, but the mechanism behind this effect is unclear. We measured arterial plasma levels of NE and other catechols during intravenous infusion of tritium-labeled NE (3H-NE) in risperidone-treated patients and compared their data with those from patients treated with clozapine or placebo. NE levels in risperidone patients were significantly higher than in placebo patients, but lower than in clozapine patients. Neither drug, however, had significant effect on plasma levels of the main neuronal metabolite of NE, dihydroxyphenylglycol (DHPG), suggesting that adrenoceptors blockade alone would not explain the NE findings. The rate of release of endogenous NE into the bloodstream (spillover) was elevated in both risperidone and clozapine patients in a manner that paralleled their NE levels; the NE clearance in both groups did not differ from placebo. Following 3H-NE infusion in risperidone-treated individuals, production of 3H-DHPG was normal, as it was in the clozapine group, suggesting that risperidone does not impede neuronal uptake or intraneuronal metabolism of NE by monoamine oxidase. Our data suggest that both risperidone and clozapine elevate plasma NE levels via enhanced neurotransmitter spillover, with risperidone producing a smaller effect.

AB - Risperidone is an atypical antipsychotic drug that increases plasma norepinephrine (NE) levels, but the mechanism behind this effect is unclear. We measured arterial plasma levels of NE and other catechols during intravenous infusion of tritium-labeled NE (3H-NE) in risperidone-treated patients and compared their data with those from patients treated with clozapine or placebo. NE levels in risperidone patients were significantly higher than in placebo patients, but lower than in clozapine patients. Neither drug, however, had significant effect on plasma levels of the main neuronal metabolite of NE, dihydroxyphenylglycol (DHPG), suggesting that adrenoceptors blockade alone would not explain the NE findings. The rate of release of endogenous NE into the bloodstream (spillover) was elevated in both risperidone and clozapine patients in a manner that paralleled their NE levels; the NE clearance in both groups did not differ from placebo. Following 3H-NE infusion in risperidone-treated individuals, production of 3H-DHPG was normal, as it was in the clozapine group, suggesting that risperidone does not impede neuronal uptake or intraneuronal metabolism of NE by monoamine oxidase. Our data suggest that both risperidone and clozapine elevate plasma NE levels via enhanced neurotransmitter spillover, with risperidone producing a smaller effect.

KW - Catecholamine

KW - Clearance

KW - DHPG

KW - Schizophrenia

KW - Spillover

KW - Tritium-labeled norepinephrine

UR - http://www.scopus.com/inward/record.url?scp=0036294116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036294116&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(02)00314-7

DO - 10.1016/S0893-133X(02)00314-7

M3 - Article

C2 - 12093603

AN - SCOPUS:0036294116

VL - 27

SP - 293

EP - 300

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 2

ER -